This study aimed to show the impairment of autonomic cardiac conduction causing bradycardia and/or electrocardiographic alterations in children affected by spinal muscular atrophy type 1 and 2 (SMA 1 and 2). Methods: We included 25 spinal muscular atrophy patients, admitted from November 2016 to May 2017. All patients underwent an electrocardiographic examination and we studied PR and QRS intervals, P-waves and QRS amplitudes, and heart rate in spinal muscular atrophy patients compared to a control group.
Results:
In all patients, we found longer PRi and QRSi (P < .05), lower P-wave and QRS complex amplitudes (P < .01), and a decreased heart rate (P < .01) with respect to controls. When we divided our patients into SMA1 and SMA2 subgroups, we found that statistical differences were maintained for P-wave and QRS complex amplitudes and heart rate, but not for PRi and QRSi with respect to controls.
Conclusion:
We suggest the hypothesis of SMN expression on cardiac tissue condition and/or autonomic cardiac conduction.
LefebvreSBurglenLReboulletS. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–165.
2.
BurghesAHBeattieCE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?Nat Rev Neurosci. 2009;10:597–609.
3.
BalrajM. Rapid molecular diagnosis of spinal muscular atrophy. Indian J Med Res. 2012;135:6–8.
DarrasBT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62:743–766.
6.
PriorTWFinangerE. Spinal muscular atrophy. In: PagonRAAdamMPArdingerHH, eds. GeneReviews®[Internet]. Seattle, WA: University of Washington; 1993-2017. First published February 24, 2000. Last updated December 22, 2016.
7.
SarachanKLValentineKGGuptaK. Solution structure of the core SMN-Gemin2 complex. Biochem J. 2012;445:361–370.
8.
RossollWBassellGJ. Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ. 2009;48:289–326.
9.
ShababiMLorsonCLRudnik-SchönebornSS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?J Anat. 2014;224:15–28.
10.
WijngaardeCABlankACStamM. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12:67.
11.
HamiltonGGillingwaterTH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19:40–50.
12.
SimoneCRamirezABucchiaM. Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?Cell Mol Life Sci. 2016;73:1003–1020.
13.
NashLABurnsJKChardonJW. Spinal muscular atrophy: more than a disease of motor neurons?Curr Mol Med. 2016;16:779–792.
14.
HeierCRDidonatoCJ. ECG in neonate mice with spinal muscular atrophy allows assessment of drug efficacy. Front Biosci. 2015;7:107–116.
15.
HeierCRSattaRLutzCDiDonatoCJ. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet. 2010;19:3906–3918.
16.
BachJR. Medical considerations of long-term survival of Werdnig-Hoffmann disease. Am J Phys Med Rehabil. 2007;86:349–355.
17.
GrottoSCuissetJMMarretS. Type 0 spinal muscular atrophy: further delineation of prenatal and postnatal features in 16 patients. J Neuromuscul Dis. 2016;3:487–495.
18.
ElkohenMVaksmannGElkohenMR. Cardiac involvement in Kugelberg-Welander disease. A prospective study of 8 cases. Arch Mal Coeur Vaiss. 1996;89:611–617.
19.
TakahashiNShimadaTIshibashiY. Cardiac involvement in Kugelberg-Welander disease: a case report and review. Am J Med Sci. 2006;332:354–356.
20.
TanakaHUemuraNToyamaY. Cardiac involvement in the Kugelbert-Welander syndrome. Am J Cardiol. 1976;38:528–532.
21.
KimuraSYokotaHTatedaK. A case of the Kugelberg-Welander syndrome complicated with cardiac lesions. Jpn Heart J. 1980;21:417–422.
22.
RoosMSarkozyAChierchiaGB. Malignant ventricular arrhythmia in a case of adult onset of spinal muscular atrophy (Kugelberg–Welander disease). J Cardiovasc Electrophysiol. 2009;20:342–344.
KostovaFVWilliamsVCHeemskerkJ. Spinal muscular atrophy: classification, diagnosis, management, pathogenesis and future research directions. J Child Neurol. 2007;22:926–945.
25.
OginoSLeonardDGRennertH. Spinal muscular atrophy genetic testing experience at an academic medical center. J Mol Diagn. 2002;4:53–58.
26.
SuYNHungCCLiH. Quantitative analysis of SMN1 and SMN2 genes based on DHPLC: a highly efficient and reliable carrier-screening test. Hum Mutat. 2005;18:1440–1463.
27.
LangRMBierigMDevereuxRB. Recommendations for chamber quantification. J Am Soc Echocardiogr. 2005;18:1440–1463.
28.
NaguehSFSmisethOAAppletonCP. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.
29.
ShababiMHabibiJYangHT. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet. 2010;19:4059–4071.
30.
GogliottiRGQuinlanKABarlowCB. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci. 2012;32:3818–3829.
31.
ShababiMHabibiJMaL. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J Mol Cell Cardiol. 2012;52:1074–1082.
32.
BevanAKHutchinsonKRFoustKD. Early heart failure in the smndelta7 model of spinal muscular atrophy and correction by postnatal scaav9-smn delivery. Hum Mol Genet. 2010;19:3895–3905.
33.
NarverHLKongLBurnettBG. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol. 2008;64:465–470.
34.
AvilaAMBurnettBGTayeAA. Increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007;117:659–671.
35.
HachiyaYAraiHHayashiM. Autonomic dysfunction in cases of spinal muscular atrophy type 1 with long survival. Brain Dev. 2005;27:574–578.
36.
AraujoAQAraujoMSwobodaKJ. Vascular perfusion abnormalities in infants with spinal muscular atrophy. J Pediatr. 2009;155:292–294.
37.
RiisP. Perspectives on the Fifth Revision of the Declaration of Helsinki. JAMA. 2000;284:3045–3056.
